Tsuyoshi Hirata
Overview
Explore the profile of Tsuyoshi Hirata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hirata T, Uehara Y, Hakozaki T, Kobayashi T, Terashima Y, Watanabe K, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100761.
PMID: 39758600
[This corrects the article DOI: 10.1016/j.jtocrr.2024.100659.].
2.
Hirata T, Watanabe K, Hosomi Y, Yoh K, Usui K, Kishi K, et al.
Jpn J Clin Oncol
. 2024 Dec;
55(3):269-274.
PMID: 39703183
Introduction: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is a first-line therapy for advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations, including both...
3.
Koganemaru S, Koyama S, Suto F, Koga M, Inaki K, Kuwahara Y, et al.
Cancer Res Commun
. 2024 Dec;
5(1):84-93.
PMID: 39679910
This biomarker study explored HER2 expression levels and immune cell characteristics that may affect response to T-DXd using tumor tissue samples collected from clinical trial participants. The results suggest that...
4.
Hirata T, Uehara Y, Hakozaki T, Kobayashi T, Terashima Y, Watanabe K, et al.
JTO Clin Res Rep
. 2024 Apr;
5(4):100659.
PMID: 38596201
Introduction: Previous studies reported an association between immune checkpoint inhibitor infusion timing and the treatment effect in metastatic NSCLC. The present study assessed the association between durvalumab infusion timing and...
5.
Hirata T, Kubota N, Fukushima K, Takami E, Kato T, Okamoto T
Oxf Med Case Reports
. 2024 Mar;
2024(3):omae009.
PMID: 38532755
An 80-year-old man presented in December with the main complaint of jaundice. Blood tests revealed hemolytic anemia and renal dysfunction. Positive syphilis serology results led to a diagnosis of untreated...
6.
Kawaguchi Y, Kawamura Y, Hirose H, Kiyokawa M, Hirate M, Hirata T, et al.
J Control Release
. 2024 Feb;
367:877-891.
PMID: 38301930
To facilitate the introduction of proteins, such as antibodies, into cells, a variety of delivery peptides have been engineered. These peptides are typically highly cationic and somewhat hydrophobic, enabling cytosolic...
7.
Hirata T, Hakozaki T
J Thorac Dis
. 2023 Aug;
15(7):3554-3556.
PMID: 37559596
No abstract available.
8.
Numata M, Haginoya N, Shiroishi M, Hirata T, Sato-Otsubo A, Yoshikawa K, et al.
Cancer Cell Int
. 2023 Feb;
23(1):36.
PMID: 36841758
Background: Mixed lineage leukemia 1-rearranged (MLL1-r) acute leukemia patients respond poorly to currently available treatments and there is a need to develop more effective therapies directly disrupting the Menin‒MLL1 complex....
9.
Hirata T, Yamamoto K, Ikeda K, Arita M
FASEB J
. 2021 Jan;
35(2):e21301.
PMID: 33421194
Laminar shear stress generated by blood flow stimulates endothelial cells and activates signal transduction, which plays an important role in vascular homeostasis. Several lines of evidence indicate that membrane and...
10.
Nishimura M, Yamashita A, Matsuura Y, Okutsu J, Fukahori A, Hirata T, et al.
J Atheroscler Thromb
. 2020 Dec;
28(11):1214-1240.
PMID: 33298635
Aims: Inflammation and hypertension contribute to the progression of atherosclerotic aneurysm in the aorta. Vascular cell metabolism is regarded to modulate atherogenesis, but the metabolic alterations that occur in atherosclerotic...